News Details

Commencement Of Pivotal Phase IV Clinical Study: The Team Behind The Scene

  2020-11-18 21:32:40

- The Company Has Lined Up A Strong Team To Support The Study

KUALA LUMPUR, 18 NOVEMBER 2020 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code:9601) has begun its Phase IV clinical study on COVID-19 vaccine with E-MO Biology Inc (“EBI”) whose key business revolves around biology research and development activities besides indicating booster polio vaccine can reduce COVID-19 SARS-COV-2 infection and severity.
The Phase IV clinical study will be led by EBI founder and managing director, Dr. Xie Qiyi (“Dr. Xie”).
With 30 years of experience in public health and infectious disease control as well as 20 years in the development of medical and diagnostic devices, Dr. Xie is also a former officer of the national immunization program of China, a current fellow of the World Health Organization (WHO) and a CDC infectious diseases control specialist.

On the other hand, the study’s principal investigator is Dr. Roderick A. Comunale, who has 35 years’ experience in nephrology and internal medicine and has been conducting COVID-19 clinical trials according to the US FDA approved protocol.

The laboratory appointed to carry out the Phase IV clinical study is America Diagnosis & GeneScan Diagnostics Inc., a California based company, of which America Diagnostics Inc. is a company that manufactures IVD diagnostics kits and raw materials. 
Together with GeneScan Diagnostics, LLC (GDX, formally America Diagnosis, Inc.), the company developed and manufactured GeneScanTM Precision DNA Analysis System with its GeneScanTM DNA Analysis Kits for quick gene identification. GDX has also adopted ISO 9001:2015 quality management system to ensure high-quality products and services.
HWGB Biotech’s General Manager, Medical & Pharmaceutical Research, Dr. Yaman Walid Kassab, said:, “The Phase IV clinical study is to gauge the safety and efficacy of the vaccine when used in a targeted population. The study is important to know how effective our use of the polio vaccine is as a base for a COVID-19 vaccine”.

Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.comhttp://subscription.hwgbbiotech.comFacebookLinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.

Dr. Xie QiYi, is the Managing Director of E-MO Biology Inc (“EBI”). He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.

Dr. Roderick A. Comunale (“Dr. Roderick”) specialised in Nephrology and Internal Medicine, in National City, California. He is currently practices at Roderick A. Comunale II MD Inc and is affiliated with Paradise Valley. Dr. Roderick is currently conducting a multi-centre clinical study entitled “Inactivated Polio Vaccine (“IPV”) in prevention of COVID-19 in high risk population in a Phase IV study", to study the effects of Inactivate Polio Vaccine-IPV.

America Diagnostics & GeneScan Diagnostics Inc., is a California company that principally involved in research, development and production of the companion diagnostics systems and biomedical assay development services.